about
Treatment of polycythemia vera and essential thrombocythemia: the role of pipobromanIncreased risk of pregnancy complications in patients with essential thrombocythemia carrying the JAK2 (617V>F) mutationA gain-of-function mutation of JAK2 in myeloproliferative disordersCALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisonsPomalidomide is active in the treatment of anemia associated with myelofibrosisBlast phase of essential thrombocythemia: A single center study.Platelet size distinguishes between inherited macrothrombocytopenias and immune thrombocytopenia.DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status.Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis.A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 Inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea.Distinct clustering of symptomatic burden among myeloproliferative neoplasm patients: retrospective assessment in 1470 patients.Ruxolitinib versus standard therapy for the treatment of polycythemia vera.Everolimus in diffuse large B-cell lymphomas.Prognostic impact of bone marrow fibrosis in primary myelofibrosis. A study of the AGIMM group on 490 patients.Efficacy of a combination of idarubicin, etoposide and intermediate-dose cytosine arabinoside as salvage therapy in relapsing or resistant unfavorable lymphoma.Polycythemia vera in young patients: a study on the long-term risk of thrombosis, myelofibrosis and leukemia.Muco-cutaneous changes during long-term therapy with hydroxyurea in chronic myeloid leukaemia.New generation small-molecule inhibitors in myeloproliferative neoplasms.Deep sequencing reveals double mutations in cis of MPL exon 10 in myeloproliferative neoplasms.Impact of allogeneic stem cell transplantation on survival of patients less than 65 years of age with primary myelofibrosis.European Bone Marrow Working Group trial on reproducibility of World Health Organization criteria to discriminate essential thrombocythemia from prefibrotic primary myelofibrosis. Haematologica 2012;97(3):360-5--comment.Acquired copy-neutral loss of heterozygosity of chromosome 1p as a molecular event associated with marrow fibrosis in MPL-mutated myeloproliferative neoplasmsRevised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project.Clinical relevance of JAK2 (V617F) mutant allele burdenLife expectancy and prognostic factors in the classic BCR/ABL-negative myeloproliferative disorders.Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet.Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference.Mutational status of myeloproliferative neoplasms.Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study.Incidence and risk factors for bleeding in 1104 patients with essential thrombocythemia or prefibrotic myelofibrosis diagnosed according to the 2008 WHO criteria.Clinical predictors of outcome in MPN.Identifying and addressing unmet clinical needs in Ph-neg classical myeloproliferative neoplasms: a consensus-based SIE, SIES, GITMO position paper.Clinical end points for drug treatment trials in BCR-ABL1-negative classic myeloproliferative neoplasms: consensus statements from European LeukemiaNET (ELN) and Internation Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT)It is time to change thrombosis risk assessment for PV and ET?Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial.Patterns of presentation and thrombosis outcome in patients with polycythemia vera strictly defined by WHO-criteria and stratified by calendar period of diagnosis.Investigational therapies targeting lymphocyte antigens for the treatment of non-Hodgkin's lymphoma.New molecular genetics in the diagnosis and treatment of myeloproliferative neoplasms.New uses for brentuximab vedotin and novel antibody drug conjugates in lymphoma.Novel agents in indolent lymphomas.
P50
Q28210858-2EF425D8-F68C-4923-992F-CBFCAB1A0C6DQ28222209-C39402CD-E607-4AE0-911D-752C0640DD5DQ29618851-AB4DC915-6A32-4B7F-B3EA-D4AD63FB6FC1Q29998841-5E43764C-CED8-44F5-8F31-FB6FF123464AQ33385644-03A6E6EE-DF6D-47DF-A85F-36C6FB950237Q33385885-8AEE8A59-A6FE-44B2-8C00-7F9660C79E4BQ33386154-8B089EAD-1B80-4E44-97BD-8CD9D8B536D8Q33393245-56D8C616-1608-4911-B431-17022611E532Q33411211-D5D93149-0135-4D51-8959-BEFF531B7B37Q33411637-F52D3FDD-C2DD-4BB9-84D2-A9BB4A25BBECQ33413428-A60C14B3-EB1A-4A42-89D7-354E6B1D8DC6Q33420037-D7C9A48B-4405-4AC9-81D6-6711C9548482Q33420346-6EED89FF-8FF1-4671-94DD-2386E7800CD3Q33432755-7EB9F776-E056-42CD-9CD3-14F39D0692BBQ33502512-4414526A-C5BB-4107-B152-0F368A1442C4Q33963986-3100B525-7EBE-49AE-AAFB-1D55073B0FFCQ34216205-DD7730FA-7EB5-404F-93D4-61B7B7FC59DDQ34634950-0E734085-02D1-437E-84FB-8D3C7179A55CQ34750599-1B6149DF-0DC6-4362-897D-381FD03C4546Q35634902-64E7EB2E-E5EB-4BDD-ACBA-B5D69A566E09Q35794393-3CF1C956-8D46-4672-8A17-37B0E7306C65Q36873306-ECDDE406-F256-4FB6-97B2-1C69BC0C79CFQ36907860-EAA4EF92-400D-4D78-9F7C-5B215C131B1FQ37059441-178A62BE-CECF-4D69-8B88-28845F3A358CQ37127245-BDAB14CE-155D-44B8-BF3E-E498A946B26AQ37163590-8C79E621-9456-48A9-87DC-CDDB5FEE52B2Q37412790-2B82EEEE-A0C6-4783-BF78-00E0DB442C77Q37763236-6573EA35-1895-40A8-9F68-ADCE217A30E3Q37900078-12872393-B0DD-4C81-9CDE-BB6A095FD378Q37934479-079F987C-160F-4D91-B4CD-DA6E7767E5FDQ38046322-0CC75DEB-1A75-4581-909A-B02E9E9E2E21Q38174710-55F35EBB-CFF2-4102-B698-6806FDF3CE18Q38242725-DA642803-7CEB-494A-BE80-07797EBCDC01Q38246159-3B1A9E67-132F-4914-BFC1-5E4D142A0743Q38393343-855F1C3E-1FDB-41DF-90EB-25EC9CA387B0Q38416243-9C4C25E5-FFC7-4E15-A0B0-631EC7FAD3BCQ38434473-52C27052-2441-44F6-9C3D-1DC8A70F85B4Q38716316-6A9D3621-90A0-474C-BB15-A27C9BE42DD2Q38896683-1AAC872C-75A3-4BFE-8FC1-36448A759179Q39431412-02566818-9286-447F-B6B9-5A27180EAED1
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Francesco Passamonti
@ast
Francesco Passamonti
@en
Francesco Passamonti
@es
Francesco Passamonti
@nl
Francesco Passamonti
@sl
type
label
Francesco Passamonti
@ast
Francesco Passamonti
@en
Francesco Passamonti
@es
Francesco Passamonti
@nl
Francesco Passamonti
@sl
prefLabel
Francesco Passamonti
@ast
Francesco Passamonti
@en
Francesco Passamonti
@es
Francesco Passamonti
@nl
Francesco Passamonti
@sl
P106
P1153
6604028719
P21
P31
P496
0000-0001-8068-5289